Briciclib

Cat. No.: HY-16366
CAS No.: 865783-99-9
Molecular Formula: C₁₉H₂₃O₁₀PS
Molecular Weight: 474.42
Target: Eukaryotic Initiation Factor (eIF); Autophagy
Pathway: Cell Cycle/DNA Damage; Autophagy
Storage:
- Powder -20°C 3 years
- Powder 4°C 2 years
- In solvent -80°C 6 months
- In solvent -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro DMSO: ≥ 31 mg/mL (65.34 mM)

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.1078 mL</td>
<td>10.5392 mL</td>
<td>21.0784 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4216 mL</td>
<td>2.1078 mL</td>
<td>4.2157 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2103 mL</td>
<td>1.0539 mL</td>
<td>2.1078 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.

IC₅₀ & Target eIF4E[1]

In Vitro Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI₅₀s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours[1].

REFERENCES

www.MedChemExpress.com